Introduction {#s1}
============

With more than 1.6 million cases diagnosed annually, lung cancer is the leading cause of cancer-related deaths in men and the second leading cause of cancer deaths in women worldwide [@pone.0054970-Jemal1]. Given the clinical burden of lung cancer, with non--small cell lung cancer (NSCLC) accounting for approximately 85% of all cases, it has become a major health problem, worldwide. Despite major advances in cancer treatment in the past two decades, the prognosis of patients with lung cancer has improved only minimally, the overall 5-year survival rate for NSCLC (all stages combined) is roughly 15% (<http://seer.cancer.gov/statfacts/html/lungb.html>).

Although TNM stage is the most significant clinical parameter to be considered on cancer prognosis, the variability of survival within staging groups requires additional parameters affecting outcome, independent of tumor stage. Since multiple gene and gene-related alterations contribute to NSCLC development and progression. Therefore, determination of the biological behavior and identification of prognostic biomarkers is important for the early detection of relapse, as well as for stratification of patients before enrollment onto their treatment regimens. There is increasing evidence that epigenetic alterations, particularly inactivation of tumor suppressor genes or tumor-related genes through promoter hypermethylation, play a dominant role in various cancers including lung cancer [@pone.0054970-Sapari1], [@pone.0054970-Zhang1]. Promoter CpG island methylation is the most widely studied and best characterized epigenetic alteration in NSCLC, providing some of the most promising markers for early detection and prediction of prognosis or treatment response in NSCLC (see review article [@pone.0054970-Lu1]).

The *p16* ^INK4A^ gene is known as a tumor suppressor gene, which functions as negative regulator of the cell cycle progression through its inhibition of cdk4/6 and subsequent blockage of the cyclin-dependent phosphorylation of the Rb [@pone.0054970-Serrano1]. Promoter silencing of *p16* ^INK4A^ through methylation lead to loss of control of the restriction point in the G1 phase of the cell cycle and favor cellular transformation [@pone.0054970-Voorhoeve1], [@pone.0054970-Merlo1], [@pone.0054970-Esteller1]. Abnormal *p16* promoter hypermethylation has been found in several types of tumor, and it is inactivated in 40% to 70% of NSCLC patients [@pone.0054970-Esteller1]. The contribution of *p16* deregulation through methylation to the carcinogenic process has been extensively studied. Moreover, bulks of observational studies evaluating its prognostic value in NSCLC have been carried out in past ten years [@pone.0054970-Kang1], [@pone.0054970-Sterlacci1], [@pone.0054970-Sasaki1], [@pone.0054970-Buckingham1], [@pone.0054970-Yoshino1], [@pone.0054970-Fischer1], [@pone.0054970-Ota1], [@pone.0054970-Kim1], [@pone.0054970-Divine1], [@pone.0054970-Wang1], [@pone.0054970-Maruyama1], [@pone.0054970-Harden1], [@pone.0054970-ZochbauerMuller1], [@pone.0054970-Kim2].

The prognostic role of *p16* methylation in NSCLC has been investigated over the past decade, with conflicting results from different literatures. Some studies concluded *p16* hypermethylation was an independent prognostic factor for dismal outcome. Some other studies did not identify this association. In order to clarify this question, we sought to conduct a systematic review and meta-analysis to estimate the prognostic importance of *p16* methylation status for overall survival (OS) and disease-free survival (DFS) in patients with NSCLC.

Materials and Methods {#s2}
=====================

Literature Search Strategy {#s2a}
--------------------------

We performed a systematic search of the relevant literature using PubMed, Web of Science and Embase databases up to June 2012 without language restrictions. We used the following search terms and their combinations: "NSCLC," "non-small-cell lung cancer," "lung cancer," "*p16*," "*p16* ^INK4a^," and "methylation." Moreover, the references in all retrieved articles were screened to identify additional articles that were not identified in the initial literature search described above.

Selection Criteria {#s2b}
------------------

To be included in this meta-analysis, the studies should meet the following criteria: 1. full text publication with details of methods available; 2. Contained data on assessment of *p16* methylation status; 3. Contained outcome data for NSCLC patients according to *p16* methylation status (outcomes were overall survival and/or disease-free survival); 4. hazard ratio (HR) for OS or DFS according to *p16* status either had to be reported or could be calculated from the sufficient data provided in the original article; 5. to avoid duplicated publications, we included the most recent report or the most complete one.

Data Extraction {#s2c}
---------------

The following information was drawn from each eligible study: first author, year of publication, number of patients participated, number of patients with *p16* methylation status, TNM stage, histology, testing material, detecting methods, and data linking *p16* methylation status and clinical outcome (OS and DFS). The whole process of data extraction was performed independently by two authors, and the disparities were solved by discussion.

Statistical Methods {#s2d}
-------------------

The hazard ratio (HR) was abstracted or calculated to quantitatively evaluate the association between *p16* methylation status and NSCLC prognosis. The summary HR for overall survival and disease-free survival were evaluated by calculating pooled Cox proportional hazard ratios and 95% confidence intervals (CI) as relevant effect measures using previously published methods. When related data were not available directly from the studies, we calculated the corresponding HR and its 95%CI using the method described by Tierney et al [@pone.0054970-Tierney1]. We then investigated the between-study heterogeneity by using the Cochran's Q test, using a significance level of p value less than 0.1. The statistic I^2^ was also used to quantitatively evaluate the heterogeneity [@pone.0054970-Higgins1]. If I^2^ greater than 50% is considered a measure of severe heterogeneity, then the random-effects model was adopted to calculate HR according to the DerSimonian--Laird method [@pone.0054970-DerSimonian1]. Otherwise, the fixed-effects model (Mantel--Haenszel method) was used [@pone.0054970-Mantel1]. The assessment of sources of heterogeneity was undertaken by meta-regression analysis and subgroup analyses. One-way sensitivity analysis was performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled HR [@pone.0054970-Lau1]. We also used inverted funnel plots and the Egger's test to examine the effect of publication bias (linear regression analysis) [@pone.0054970-Egger1]. All p values were 2-sided and less than 0.05 was considered as significance. All analyses were carried out on STATA 11.0 software platform (Stata Corporation, College Station, TX).

Results {#s3}
=======

Selection and Characteristics of Studies {#s3a}
----------------------------------------

By the initial literature search, 145 records were identified regarding the association of *p16* methylation status and NSCLC survival; 111 studies were excluded after screening the titles or abstracts because they were either review articles, abstracts, no on human being, duplicate publication, or studies irrelevant to the current theme (mainly on cancer early diagnosis). Thirty-four relevant studies were selected for detailed evaluation. Nine were excluded for the systematic review after full assessment (7 were lacking relevant survival data, another 2 were duplications). Of the 25 remained studies, eighteen studies were eligible for the meta-analysis [@pone.0054970-Kang1], [@pone.0054970-Buckingham1], [@pone.0054970-Yoshino1], [@pone.0054970-Fischer1], [@pone.0054970-Ota1], [@pone.0054970-Wang1], [@pone.0054970-Maruyama1], [@pone.0054970-Kim2], [@pone.0054970-Toyooka1], [@pone.0054970-Kim3], [@pone.0054970-Safar1], [@pone.0054970-Tanaka1], [@pone.0054970-Gu1], [@pone.0054970-Sugio1], [@pone.0054970-Yanagawa1], [@pone.0054970-Brock1], [@pone.0054970-Alaa1], [@pone.0054970-Kim4], 7 provided insufficient data for performing a quantitative aggregation [@pone.0054970-Sasaki1], [@pone.0054970-Divine1], [@pone.0054970-Harden1], [@pone.0054970-Bradly1], [@pone.0054970-Shimamoto1], [@pone.0054970-Fu1], [@pone.0054970-Niklinska1].

The main features of the 25 studies eligible for the systematic review are shown in [Table 1](#pone-0054970-t001){ref-type="table"}. The number of patients included across all studies varied from 43 to 335. Among the 25 studies, 13 reported that *p16* hypermethylation was an unfavorable indicator of survival; the other 12 studies didn't found this association. There were 18 studies containing 2432 patients had sufficient survival data for quantitative aggregation, among which, 14 studies used methylation-specific PCR (MSP) to assess gene methylation status, and 4 used quantitative MSP (Q-MSP) to determine its methylation status. Seventeen studies dealt with NSCLC of all histological subtypes, one with adenocarcinoma only [@pone.0054970-Tanaka1]. Moreover, five trials reported the results of adenocarcinoma in stratified analysis [@pone.0054970-Toyooka1], [@pone.0054970-Kim3], [@pone.0054970-Tanaka1], [@pone.0054970-Gu1], [@pone.0054970-Alaa1]. Twelve trials detected *p16* methylation by using fresh frozen tissue and 5 using formalin-fixed paraffin-embedded (FFPE) specimen, only one using peripheral blood as sample [@pone.0054970-Fischer1].

10.1371/journal.pone.0054970.t001

###### The main characteristics and results of eligible studies evaluating p16 hypermethylation and NSCLC patients' survival.

![](pone.0054970.t001){#pone-0054970-t001-1}

  First author                              Year   Country   Number   Method    M     U     Stage       Material     Histology   Estimate    Results            OS                    DFS
  ---------------------------------------- ------ --------- -------- -------- ----- ----- ---------- -------------- ----------- ----------- --------- ---------------------- ----------------------
  Duk-Hwan Kim [@pone.0054970-Kim2]         2001     USA      185      MSP     51    134    I--IV     fresh tissue     NSCLC        Cox         S       4.72(1.02--21.85 )             NA
  Niklinska [@pone.0054970-Niklinska1]      2001   Poland      52      MSP     16    36     I--II     fresh tissue     NSCLC        Cox         S               NA                     NA
  Fu [@pone.0054970-Fu1]                    2003    China      64      MSP     36    28     I--III    fresh tissue     NSCLC        NA          S               NA                     NA
  Harden [@pone.0054970-Harden1]            2003     USA       90      MSP     15    75       I       fresh tissue     NSCLC        NA         NS               NA                     NA
  Maruyama [@pone.0054970-Maruyama1]        2004     USA      124      MSP     25    99     I--IV     fresh tissue     NSCLC        Cox        NS        0.81(0.43--1.52)              NA
  Shimamoto [@pone.0054970-Shimamoto1]      2004    Japan      45      MSP     17    28     I--III    fresh tissue     NSCLC       K--M         S               NA                     NA
  Toyooka [@pone.0054970-Toyooka1]          2004    Japan     351      MSP     86    265    I--III    fresh tissue     NSCLC        Cox         S        1.82(1.10--3.00)              NA
                                                              105                                     fresh tissue      ADC                     S        2.57(1.15--5.76)              NA
  Wang [@pone.0054970-Wang1]                2004     USA      119      MSP     58    61    I--IIIA    fresh tissue     NSCLC       K--M         S        2.26(1.26--4.06)              NA
                                                               49      MSP     24    25      IIIA     fresh tissue     NSCLC       K--M         S        2.72(1.14--5.13)       1.46(1.14--6.81)
                                                               70      MSP     37    33     I--II     fresh tissue     NSCLC       K--M         S        1.69(1.07--6.98)       1.51(1.21--7.63)
  Divine [@pone.0054970-Divine1]            2005              147      MSP     63    84       I       FFPE tissue       ADC        K--M        NS               NA                     NA
  Young Tae Kim [@pone.0054970-Kim3]        2005    Korea      61      MSP     41    20     I--III    fresh tissue     NSCLC        Cox        NS      0.390 (0.066--2.293)   0.509 (0.164--1.577)
                                                               72      MSP     60    12     I--IV     fresh tissue      ADC         Cox        NS      0.176 (0.029--1.074)            NA
  Safar [@pone.0054970-Safar1]              2005     USA      105      MSP     41    64     I--IV     FFPE tissue      NSCLC        Cox        NS        0.73(0.43--1.23)              NA
  Tanaka [@pone.0054970-Tanaka1]            2005    Japan      57      MSP     23    34     I--III    FFPE tissue       ADC        K--M         S        1.39(1.09--4.71)              NA
  Gu [@pone.0054970-Gu1]                    2006     USA      155     Q-MSP    34    121    I--III    fresh tissue     NSCLC        Cox         S        1.95(1.12--3.39)              NA
                                                                               18    59               fresh tissue      ADC         Cox        NS       1.24 (0.59--2.60)              NA
  Jin Seuk Kim [@pone.0054970-Kim4]         2006    Korea     335      MSP     117          I--IV     FFPE tissue      NSCLC        NA         NS               NA                     NA
                                                              198      MSP                    I       FFPE tissue      NSCLC        Cox         S        2.67(1.21--7.64)      2.03 (1.09--6.23)
  Ota [@pone.0054970-Ota1]                  2006    Japan     244     Q-MSP    87           I--IV     FFPE tissue      NSCLC        Cox         S      1.005(1.003--1.008)             NA
  Sugio [@pone.0054970-Sugio1]              2006    Japan     224      MSP     49           I--IV     fresh tissue     NSCLC     log--rank     NS        2.31(0.64--9.82)              NA
  Fischer [@pone.0054970-Fischer1]          2007   Germany     92      MSP     22    63    IIIB--IV   blood sample     NSCLC     log-rank      NS        1.47(0.61--3.57)              NA
  Yanagawa [@pone.0054970-Yanagawa1]        2007    Japan     101      MSP     27    74     I--III    fresh tissue     NSCLC        Cox        NS        0.93(0.33--2.62)              NA
  Brock [@pone.0054970-Brock1]              2008     USA      187      MSP                    I       FFPE tissue      NSCLC        Cox         S               NA              3.55(1.77--7.13)
  Alaa [@pone.0054970-Alaa1]                2009    Japan      88      MSP     30    58     I--IV     fresh tissue     NSCLC        Cox        NS         1.4(0.6--3.2)                NA
                                                               43      MSP     10    33     I--IV     fresh tissue      ADC         Cox         S         2.4(1.8--69.7)               NA
  Yoshino [@pone.0054970-Yoshino1]          2009    Japan      44      MSP     11    33       IA      fresh tissue     NSCLC       K--M         S       2.36 (1.14--9.90)      2.18 (1.56--11.2)
  Bradly [@pone.0054970-Bradly1]            2010     USA      196      MSP                  I--II     fresh tissue     NSCLC        NA          S               NA                     NA
  Buckingham [@pone.0054970-Buckingham1]    2010     USA      132     Q-MSP                 I--II     fresh tissue     NSCLC       K--M        NS       1.16 (0.67--2.02)      1.35 (0.74--2.46)
  Sasaki [@pone.0054970-Sasaki1]            2010    Japan     221      MSP     91           I--IV     fresh tissue     NSCLC        NA         NS               NA                     NA
  Kang [@pone.0054970-Kang1]                2012    Korea      80     Q-MSP     9           I--III    fresh tissue     NSCLC       K--M         S       2.31 (2.10--51.72)             NA

MSP, Methylation-specific PCR; Q-MSP, quantitative methylation-specific PCR; FFPE, formalin-fixed paraffin-embedded; ADC, adenocarcinoma; S, significant; NS,not significant; NA, not available.

Meta-analysis Results {#s3b}
---------------------

Using the methods described above, the overall survival and/or disease-free survival of 2432 patients in 18 studies were analyzed. The main results of this meta-analysis are summarized in [Table 2](#pone-0054970-t002){ref-type="table"}.

10.1371/journal.pone.0054970.t002

###### The results of meta-analysis on NSCLC overall survival and p16 methylation.

![](pone.0054970.t002){#pone-0054970-t002-2}

                      Pts number      HR (95%CI)         Heterogeneity            
  ------------------ ------------ ------------------- ------------------- ------- -------
  All studies            2432      1.36 (1.08--1.73)   41.60 (d.f. = 18)   0.001   56.7%
  Subgroups                                                                       
  Detecting method                                                                
   MSP                   1821      1.40 (1.02--1.92)   26.69 (d.f. = 14)   0.021   47.5%
   Q-MSP                 611       1.26 (0.87--1.82)    6.80 (d.f. = 3)    0.079   55.9%
  Stage                                                                           
   I                     242       2.53(1.26--5.11)     0.03 (d.f. = 1)    0.865   0.0%
   I--II                 202       1.28(0.79--2.06)     0.46 (d.f. = 1)    0.498   0.0%
   I--III                805       1.61(1.19--2.19)     4.57 (d.f. = 5)    0.470   0.0%
   I--IV                 1091      1.00(0.71--1.41)    11.39 (d.f. = 6)    0.077   47.3%
  Histology                                                                       
   NSCLC                 2303      1.41(1.10--1.79)    37.28 (d.f. = 16)   0.002   57.1%
   ADC                   412       1.56(0.84--2.88)     9.76(d.f. = 5)     0.082   48.8%
  Sample type                                                                     
   Fresh tissue          1736      1.50(1.11--2.01)    20.64(d.f. = 13)    0.080   37.0%
   FFPE tissue           604       1.10(0.77--1.57)     6.50(d.f. = 3)     0.090   53.8%

MSP, Methylation-specific PCR; Q-MSP, quantitative methylation-specific PCR; FFPE, formalin-fixed paraffin-embedded; ADC, adenocarcinoma; Pts, patients.

Overall survival: of the 17 evaluable studies for OS, the promoter hypermethylation of *p16* was associated with a significant poor impact on NSCLC survival. However, the test for heterogeneity was highly significant (P = 0.001, I^2^ = 56.7%). Consequently, we applied a random-effect model in calculating the aggregated HR, which was 1.36 (95% CI: 1.08--1.73) (as [Figure 1](#pone-0054970-g001){ref-type="fig"} shows). We also conducted subgroup analyses on sample type, detecting methods, histology, and tumor stage. When grouped according to the sample type of individual studies, the combined HRs of fresh frozen tissue and FFPE specimen were 1.50 (95% CI: 1.11--2.01) and 1.10 (95% CI: 0.77--1.57), respectively. When grouped according to the method of *p16* methylation detection used, the combined HR was 1.40 (95% CI: 1.02--1.92) for MSP and 1.26 (95% CI: 0.87--1.82) for Q-MSP. Stratified by histology, the combined HR of the 16 studies reporting NSCLC as a whole indicated that patients with *p16* hypermethylation had a risk of death 1.41 times greater than patients without *p16* hypermethylation (HR = 1.41, 95% CI: 1.10--1.79). However, no such statistical significant death risk when pooling the 6 trials of adenocarcinoma subtype (HR = 1.56, 95% CI: 0.84--2.88). We also analyzed the data according to tumor stage. For the studies focusing on stage I and I-III, the aggregation produced statistically significant HRs without significant between-study heterogeneity (2.53 and 1.61, respectively). No significant association was found in I-II and I-IV subgroups.

![Forest plot showing the association between *p16* methylation and overall survival of NSCLC.\
The summary HR and 95% CIs were shown (random-effects model analysis).](pone.0054970.g001){#pone-0054970-g001}

Disease-free survival: there were seven studies with 741 patients reported the association of *p16* promoter hypermethylation and disease-free survival. NSCLC patients with *p16* promoter hypermethylation were significantly correlated with shorter DFS, and the combined HR was 1.68 (95% CI: 1.12--2.52) without significant heterogeneity (p = 0.134, as [figure 2](#pone-0054970-g002){ref-type="fig"} shows). In the stratified analyses, *p16* methylation was significantly correlated with poor DFS according to MSP method, with a combined HR of 1.75 (95% CI: 1.07--2.87). When four trials using fresh tissue pooled, null association was observed (HR = 1.34, 95% CI: 0.92--1.96). The two studies with 358 cases using FFPE specimen were also combined, and the pooled HR was 2.86 (95% CI: 1.66--4.92).

![Forest plot showing the association between *p16* methylation and disease-free survival of NSCLC.\
The summary HR and 95% CIs were shown (random-effects model analysis).](pone.0054970.g002){#pone-0054970-g002}

Sensitivity Analyses and Publication Bias {#s3c}
-----------------------------------------

Sensitivity analyses were conducted by omitting one study per time in an attempt to check if individual study affected the final results of both OS and DFS. All the results were not materially altered. The visualization of the funnel plots for OS and DFS seemed asymmetrical. Egger's test was used to provide statistical evidence for funnel plot symmetry. The results did not suggest significant evidence of publication bias: OS (Egger's test, p = 0.05) and DFS (Egger's test, P = 0.06).

Discussion {#s4}
==========

No consensus has been reached regarding whether *p16* promote methylation is a prognostic marker in NSCLC patients, and it has attracted considerable attention. The present meta-analysis summarized for the first time all of the available researches on the impact of the promoter methylation of *p16* on the survival of NSCLC. The overall pooled analyses of the associations between *p16* methylation and NSCLC outcomes demonstrated negative impacts on patients with hypermethylation. As in the subgroup analyses for OS, the results suggested that *p16* methylation was a poor prognostic indicator using MSP method, whereas those using Q-MSP method combined didn't get a similar conclusion. Individual study selected various cutoff points of the ratio for *p16* gene to dichotomize the patients into methylated and unmethylated groups might partly explain the disparity. When stratified analysis was conducted about different stages of NSCLC, the associations were also found in stages I to III, but not I-IV, with relatively larger sample pooled indicating that late-stage NSCLC patient confounded the observation of *p16* methylation on survival. About test materials, we found that the association was significant by using fresh tissue, but not paraffin block. The reliability and reproducibility of the previously developed MSP method require high-quality DNA, often from a fresh frozen specimen. In most clinical settings, although paraffin specimens are available for easy transport and storage, it might cause false negative. One study reported that MSP can provide reliable gene methylation status on only two-thirds of formalin-fixed paraffin-embedded tumor specimens compared with fresh frozen tissues [@pone.0054970-Hegi1]. When histology type was taken into account, a dismal impact on survival was observed in NSCLC, but not in adenocarcinoma which was based on the data of 6 studies. As for DFS, cases with *p16* promoter hypermethylation were significantly correlated with shorter DFS and no evidence of significant heterogeneity was found, suggesting a short recurrence. In subgroup analysis according to the different techniques used to detect *p16* methylation, an adverse impact on DFS was observed with MSP method. Interestingly, such an association with DFS was found in the studies pooled using FFPE specimens, while fresh frozen tissues were not.

The search for a potential prognostic role of *p16* methylation in NSCLC survival is based on its frequent hypermethylation in NSCLC and also on its potential interference with most pathways implicated in tumorigenesis. The role of *p16* methylation in carcinogenesis has widely been investigated by *in vitro* experiments and by *in vivo* analyses based on animal models [@pone.0054970-Kato1], [@pone.0054970-Honoki1], [@pone.0054970-Patel1]. Hypermethylation of CpG islands located in the promoter regions of *p16* is now firmly established as an important mechanism for gene inactivation, and the CpG island hypermethylation has been described in almost every tumor type [@pone.0054970-Esteller2]. The meta-analysis results suggested that *p16* methylation status could be used as a stratified factor for NSCLC patient survival though with slight significant associations. Increasing data suggests that DNA methylation measurements of the promoter regions of specific genes have the potential to supply additional or superior information to that available from the existing cancer markers. These early finding now requires validation, initially in retrospective studies but ultimately in large prospective clinical studies. In addition to clinical validation, assays for methylated genes must be robust, simple, standardized, evaluated in external quality assurance schemes and made available at affordable costs. Only then, can patients expect to benefit from measurement of these markers [@pone.0054970-Duffy1].

To interpret the results of the present meta-analysis, some limitations should be taken into account. First, one limitation is that 7 trials had to be excluded from the meta-analysis because they did not provide sufficient data for aggregation. Four out of seven trials detected that *p16* methylation positive related to poor prognosis. However, of the other 3 trials with negative results, two of which carried out the research using relatively larger samples (over 200 patients) still found null association. Moreover, it is known that negative studies are less frequently published or, if they are, with less detailed results, making them less assessable. Although Egger's test didn't reach statistical significant, publication bias may influence the results and leads to positive association. Second, eleven out of 18 (61.1%) studies reported HR and corresponding 95%CIs. In order to reduce the missing data, we managed to contact the authors and estimate the outcome with the help of a spreadsheet provided by Tierney *et al* [@pone.0054970-Tierney1]. In spite of the seven outcomes calculated from Kaplan--Meier curve or log-rank test may have introduced some imprecision, we felt this was a risk worth taking in view of the alternative. This situation also highlights the importance of a uniform reporting of study results about survival outcomes. Third, our analysis was based on literatures and not individual patient data. The unavailability of individual patient data could not allow us to correct the potential confounding factors. So, the multivariate analysis cannot be performed, and it cannot be exactly known whether *p16* methylation is a prognostic factor, independently of as known clinical factors, such as age, sex, differentiation, stages, and performance status. Therefore, the results must be interpreted cautiously, because literature-based meta-analysis provides more bias and is less reliable than the individual patient data based analysis [@pone.0054970-Stewart1]. Finally, moderately significant heterogeneity was found in this meta-analysis (I^2^ = 56.7%) for overall survival. Most of the included studies were retrospective and differed in their study designs, such as patient selection, chemotherapeutic protocol and follow-up period. Some trial included patients receiving surgery or radiotherapy in addition to the platinum-based chemotherapy, thus adding the heterogeneity between studies. So we performed the analysis using random-effects model which considers the between-study heterogeneity. Moreover, stratified analyses would be helpful to reduce the heterogeneity and provide additional useful information.

On the basis of the results of this analysis, we support the hypothesis that NSCLC patients with the promoter hypermethylation of *p16* have moderately risk of recurrence and death in all populations considered. Whether p16 methylation testing could move toward routine clinical application as a prognostic tool in NSCLC, it depends on further study validation. Future studies should have a more strict design, with large sample sizes to increase statistical power, a uniform way of analyzing survival outcomes, and a long and specified follow-up period.
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